Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Traditionally MCN is treated with a high dose of prednisolone, which induces remission in
60-90% of patients. Prednisolone treatment contains numerous side effects and the current
dose is empiric. Given the lack of efficacy evidence and the risk associated with the
currently accepted treatment regimen there is a need to characterize the outcome in MCN
further, and to establish new, and potentially less toxic treatment regimens.
The aim is to examine if treatment with reduced dose of prednisolone in combination with
activated vitamin D is as effective as standard high dose prednisolone in achieving remission
and preventing relapse in MCN, and if reduced dose prednisolone is associated with fewer side
effects compared to standard dose. Furthermore, the study will examine the influence of
prednisolone metabolism on the efficacy and side effects of prednisolone in the treatment of
MCN.